ANN ARBOR, Michigan, May 1, 2026, 14:01 EDT
- ARCHIMED is picking up Esperion Therapeutics for $3.16 a share in cash, tacking on a non-tradeable contingent value right that depends on hitting future sales targets.
- ESPR surged about 56%, landing close to the cash bid. With that, the stock’s price is barely pricing in much of the potential additional payout.
- Just weeks after picking up Corstasis and adding Enbumyst—a nasal spray diuretic for excess fluid—Esperion has landed this deal.
ARCHIMED is acquiring Esperion Therapeutics Inc. in a deal that could reach roughly $1.1 billion, both companies announced Friday. Esperion’s shares, which trade on the Nasdaq, surged after news broke that the Michigan-based drugmaker will go private.
Esperion shareholders are looking at $3.16 per share in cash—a 58% bump over where the stock finished on April 30—plus a contingent value right for every share they own. The CVR? Basically a chance at more cash if certain milestones are met, potentially adding up to a $100 million payout.
The market’s moving fast to price Esperion close to the cash offer. Shares changed hands at $3.115 as of 1:44 p.m. EDT—up 55.75% on the day and just shy of the announced cash bid, market data show.
The deal comes as Esperion pushes to build a more stable commercial platform. For 2025, the company reported net product sales of $159.6 million from its cholesterol drugs Nexletol and Nexlizet, alongside $243.6 million in collaboration revenue. Bottom line: Esperion still posted a net loss of $22.7 million.
Esperion CEO Sheldon Koenig called the ARCHIMED agreement “attractive and immediate upfront value” for shareholders, while also keeping the door open for potential milestone payouts down the line. ARCHIMED partner Justin Bateman pointed to Esperion’s “strong foundation” in cardiovascular and primary care markets. Esperion Therapeutics, Inc.
The debate on value centers on the CVR. If U.S. net sales for bempedoic-acid drugs—Nexletol and Nexlizet among them—hit $300 million in 2027, holders stand to collect up to $40 million, with the total payout unlocked at $350 million in sales. There’s another possible $60 million tied to bumetanide products like Enbumyst, but that only comes into play if U.S. net sales climb to $160 million in any year before Dec. 31, 2030.
Cantor Fitzgerald’s Kristen Kluska flagged that the deal looks underwhelming, considering Esperion’s U.S. peak sales are projected near $1.5 billion. She pointed to doubts about how much market share the company can actually capture, noting that with a $500 million peak sales scenario, Esperion stock would have sat near $3 before the buyout.
Esperion is focused on LDL-C—low-density lipoprotein cholesterol, known as the “bad” kind. Its flagship products are Nexletol and Nexlizet, both non-statin, once-daily options meant for patients who can’t get their LDL-C down and stay at risk for heart problems. Esperion Therapeutics, Inc.
Back in March, the company moved to broaden its cardiovascular lineup, announcing plans to acquire Corstasis Therapeutics, the firm behind Enbumyst—a bumetanide nasal spray. According to Esperion, the product got the green light from the U.S. Food and Drug Administration in September 2025, targeting edema associated with congestive heart failure, liver disease, and kidney disease in adults.
Competition is fierce. Esperion’s annual report calls out entrenched rivals: low-cost generic statins and ezetimibe, plus injectable PCSK9s like Amgen’s Repatha, Regeneron and Sanofi’s Praluent, and Novartis’ Leqvio. So ARCHIMED gets a commercial asset—just not a monopoly.
Still, there’s plenty that could go wrong for investors counting on the full payout. Esperion shareholders haven’t signed off yet, and the merger has hurdles: U.S. antitrust approval, a required non-U.S. signoff, plus conditions that have to be met before closing. According to the 8-K, those CVRs aren’t tradeable, don’t come with voting or dividend rights, and could end up worthless if the milestones aren’t hit.
Esperion’s board gave the green light to the deal with a unanimous vote, urging shareholders to back the move. Closing is targeted for the third quarter. Once that’s done, Esperion goes private and its Nasdaq listing disappears.
